State Street Corporation filed a Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 3,301,893 shares of Vera Therapeutics Inc common stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: State Street Corporation reported beneficial ownership of 3,301,893 shares of Vera Therapeutics Inc common stock, representing 4.6% of the class.
  • Shared voting power: State Street disclosed shared voting power over 3,148,448 shares, with sole voting power of zero.
  • Shared dispositive power: The filing reported shared dispositive power over all 3,301,893 shares, with sole dispositive power of zero.
  • Triggering event date: The date of the event requiring the filing was September 30, 2026.
  • Filing type: State Street identified itself as a parent holding company (type "HC") under Rule 13d-1(b)(1)(ii)(G).
  • Subsidiaries involved: The filing identifies SSGA Funds Management, Inc., State Street Global Advisors Europe Limited, State Street Global Advisors Limited, State Street Global Advisors Trust Company, and State Street Global Advisors, Ltd., each classified as an investment adviser (IA), as the relevant subsidiaries.

State Street's Schedule 13G Position in Vera Therapeutics as of September 30, 2026

State Street Corporation, headquartered at One Congress Street, Suite 1, Boston, MA 02114, submitted a Schedule 13G disclosing its beneficial ownership position in Vera Therapeutics Inc, whose common stock carries CUSIP number 92337R101. According to the filing, the event triggering the disclosure occurred on September 30, 2026, and the statement was signed on November 9, 2026 by Alok Maheshwary, Senior Vice President of State Street Corporation.

The filing reports aggregate beneficial ownership of 3,301,893 shares, equal to 4.6% of the outstanding common stock of Vera Therapeutics Inc, whose principal executive offices are located at 170 Harbor Way, 3rd Floor, South San Francisco, California 94080. State Street reported zero sole voting power and zero sole dispositive power over these shares. Shared voting power was reported at 3,148,448 shares, while shared dispositive power covered the full 3,301,893 shares.

State Street filed as a parent holding company pursuant to Rule 13d-1(b)(1)(ii)(G), and the filing identifies five investment adviser subsidiaries through which the reported shares are held: SSGA Funds Management, Inc.; State Street Global Advisors Europe Limited; State Street Global Advisors Limited; State Street Global Advisors Trust Company; and State Street Global Advisors, Ltd. The filing certifies, as required, that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

State Street Corporation disclosed a 4.6% beneficial ownership stake, totaling 3,301,893 shares of Vera Therapeutics Inc common stock, via a Schedule 13G filing signed November 9, 2026 and reflecting holdings as of September 30, 2026.